Eton Pharmaceuticals (ETON) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 159.5% versus a gain of 3.5%. Over five years, ETON leads with a +953.4% price change compared with -8.4% for SNDX. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.47 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | SNDX |
|---|---|---|
| Share price | $54.50 | $16.51 |
| Market cap | $1.56B | $1.47B |
| 1-day change | -0.70% | -3.05% |
| YTD return | +224.54% | -18.94% |
| 1-year return | +159.48% | +3.53% |
| 5-year return | +953.36% | -8.39% |
| P/E ratio (TTM) | 136.24 | — |
| Forward P/E | 21.12 | — |
| EPS (TTM) | $0.40 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $66.37 | $25.59 |
| 52-week low | $14.27 | $12.99 |
| Distance from 52-week high | -17.89% | -35.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +30.29% | +127.44% |
| Average volume | 606.07K | 1.54M |
| Shares outstanding | 28.58M | 89.30M |
| Employees | 44 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed SNDX by 156.0 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
ETON vs SNDX FAQ
Which is bigger, Eton Pharmaceuticals or Syndax Pharmaceuticals?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $1.47B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, ETON or SNDX?
ETON returned +159.48% over the past 12 months, compared with +3.53% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.